These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36494600)

  • 1. BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2.
    Konrat J; Rösler W; Roiss M; Meier-Abt F; Widmer CC; Balabanov S; Manz MG; Zenz T
    Ann Hematol; 2023 Feb; 102(2):403-406. PubMed ID: 36494600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor of BRAF
    Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
    Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
    Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.
    Tiacci E; Mancini A; Marchetti M; D'Elia GM; Candoni A; Morotti A; Romano A; Gozzetti A; Broccoli A; De Carolis L; Bruna R; Tisi MC; Selleri C; Capponi M; Vallisa D; Cattaneo C; Della Porta MG; Busca A; Falini B; Massaia M; Bertù L; Pulsoni A; Rivela P; Corradini P; Passamonti F
    Br J Haematol; 2023 May; 201(3):411-416. PubMed ID: 36541031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing neutralization antibody levels following vaccination against SARS-CoV-2 in the elderly: an observational study in Southern Moravia, Czech Republic.
    Mravčík V; Husa P; Kumpanová Valachovičová S; Vobořil J
    Epidemiol Mikrobiol Imunol; 2022; 71(1):9-20. PubMed ID: 35477266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.
    Dietrich S; Pircher A; Endris V; Peyrade F; Wendtner CM; Follows GA; Hüllein J; Jethwa A; Ellert E; Walther T; Liu X; Dyer MJ; Elter T; Brummer T; Zeiser R; Hermann M; Herold M; Weichert W; Dearden C; Haferlach T; Seiffert M; Hallek M; von Kalle C; Ho AD; Gaehler A; Andrulis M; Steurer M; Zenz T
    Blood; 2016 Jun; 127(23):2847-55. PubMed ID: 26941398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the biology and treatment options for hairy cell leukemia.
    Jain P; Pemmaraju N; Ravandi F
    Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
    Handa S; Lee JO; Derkach A; Stone RM; Saven A; Altman JK; Grever MR; Rai KR; Shukla M; Vemuri S; Montoya S; Taylor J; Abdel-Wahab O; Tallman MS; Park JH
    Blood; 2022 Dec; 140(25):2663-2671. PubMed ID: 35930750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF in the cross-hairs.
    Geyer MB; Abdel-Wahab O; Tallman MS
    Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
    Kreitman RJ; Arons E
    Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
    Rastawicki W; Płaza K
    Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
    Falini B; De Carolis L; Tiacci E
    Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.
    Drulovic J; Ivanovic J; Martinovic V; Tamas O; Veselinovic N; Cujic D; Gnjatovic M; Mesaros S; Pekmezovic T
    Mult Scler Relat Disord; 2021 Sep; 54():103150. PubMed ID: 34298478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2.
    Bertram S; Blazquez-Navarro A; Seidel M; Hölzer B; Seibert FS; Doevelaar A; Rohn B; Zgoura P; Witte-Lack A; Skrzypczyk S; Scholten D; Kisters K; Babel N; Westhoff TH
    Sci Rep; 2022 Apr; 12(1):6243. PubMed ID: 35422075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials.
    Robak T; Robak P
    Expert Opin Investig Drugs; 2023 Apr; 32(4):311-324. PubMed ID: 36931901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.